GLP-1 Market
LLY $1137.82 ▲ +0.2% NVO $41.71 ▼ -1.9% PFE $27.46 ▼ -0.3% VKTX $29.52 ▼ -1.4% KLRA $12.70 ▼ -5.6% GPCR $35.50 ▼ -8.9% RHHBY $55.15 ▲ +0.4%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

controlled-ileal-release nicotinic acid as multiple dose /day

Company
University Hospital Schleswig-Holstein
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 17, 2026

Find a Clinical Trial Near Me

See recruiting studies for controlled-ileal-release nicotinic acid as multiple dose /day and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07286747

    Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT)

    Not yet reported University Hospital Schleswig-Holstein 390 participants Est. completion 2028-12-31 6 sites
    Prediabetes
    View official trial listing →
  • Completed NCT NCT06378125

    Evaluation of Safety and Pharmacokinetics of Oral Controlled-ileal-release Nicotinic Acid (CIR-NA) Compared to Immediate-release Nicotinic Acid and Placebo in Healthy Subjects and Subjects With Prediabetes

    Not yet reported University Hospital Schleswig-Holstein 60 participants Est. completion 2024-11-12 1 site Stand-alone
    Other conditions: Safety Issues, Pharmacokinetic
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: controlled-ileal-release nicotinic acid as multiple dose /day, controlled-ileal-release nicotinic acid as multiple dose 100 mg/day, CIR-NA, controlled-ileal-release nicotinic acid as multiple dose 200 mg/day

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.